Researchers at Trinity College Dublin have reported the first clinical evidence of blood-brain barrier disruption and associated inflammation in living individuals suspected of having Chronic Traumatic Encephalopathy, according to a Scientific American article published on March 21. The study, released in Science Translational Medicine, found that the blood-brain barrier may remain compromised and permeable for decades following an athlete's retirement from sports involving repetitive head trauma.
When the blood-brain barrier's integrity becomes compromised, inflammatory molecules and pathogenic toxins in the bloodstream can enter the brain, triggering neuroinflammation that can lead to abnormal accumulation of tau protein, a hallmark indicator of CTE. Researchers observed that former athletes enrolled in the study appeared to exist in a persistent state of chronic hyperinflammation. The Trinity study adds to growing evidence indicating that systemic inflammation is a key driver of neuroinflammation associated with disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.
Sigyn Therapeutics disclosed that this research supports the potential use of its CardioDialysis technology to treat neuroinflammatory diseases. CardioDialysis is a next-generation blood purification technology that enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream. Given its broad-spectrum mechanism, CardioDialysis is uniquely positioned to emerge as a potential adjunct therapy for neuroinflammatory conditions.
The Scientific American article, accessible at https://www.scientificamerican.com/article/brains-protective-barrier-stays-leaky-for-years-after-playing-contact-sports/, coincides with the journal study and highlights the long-term consequences of contact sports on brain health. Sigyn Therapeutics CEO Jim Joyce stated that CardioDialysis may play a meaningful role in slowing the progression of neuroinflammatory disorders, particularly in high-risk individuals or during early disease stages. "The dual reduction of inflammatory and pathogenic factors from the bloodstream could help stabilize the blood-brain barrier, which would limit the leakage of harmful molecules into the brain," Joyce concluded.
Sigyn Therapeutics is pursuing a strategic transaction focused on using CardioDialysis to reduce systemic inflammation associated with traumatic brain injury. The company's lead clinical indication for CardioDialysis remains the treatment of cardiovascular disease, the leading cause of death worldwide. The technology aims to reduce circulating inflammatory mediators that fuel cardiovascular disease progression while simultaneously lowering levels of cholesterol-transporting lipoproteins that contribute to heart attacks, strokes, and other Major Adverse Cardiovascular Events.
This development is significant because it connects emerging research on blood-brain barrier dysfunction with a potential therapeutic approach that could address multiple neuroinflammatory conditions. The implications extend beyond former athletes to anyone affected by neurodegenerative diseases where systemic inflammation plays a role. If successful, CardioDialysis could represent a new approach to managing conditions that currently have limited treatment options, potentially slowing disease progression and improving patient outcomes across multiple neurological disorders.
